PEG-Cactus Oligopeptide Rapamycin Conjugates for Drug Loading
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Rapamycin derivatives face challenges with low bioavailability, poor water-solubility, and stability issues, limiting their effectiveness in clinical applications, despite their immunosuppressive and antitumor properties.
Innovation Solution
The development of polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives, where a cactus oligopeptide is used to bond with polyethylene glycol, allowing multiple rapamycin molecules to be linked to each PEG terminal group, enhancing water-solubility, bioavailability, and stability through a more complete amidation reaction process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional PEGylation method is used to improve water-solubility of rapamycin, then water-solubility is improved, but drug loading rate is low because each terminal group bonds with only one drug molecule
Solution Approach 1:
The patent segments the PEG molecule into multiple terminal groups, each capable of independently bonding with rapamycin molecules. This segmentation allows one PEG molecule to carry multiple drug molecules, significantly increasing the drug loading rate while maintaining the overall molecular structure's functionality.
Solution Approach 2:
The PEG terminal groups are designed to have universal bonding capability with multiple rapamycin molecules simultaneously. Each terminal group can independently fulfill the same function of drug attachment, creating a multi-functional structure that increases drug capacity without proportionally increasing molecular complexity.
2Reliability
If rapamycin derivatives are developed to enhance immunosuppressive and antitumor activity, then therapeutic effectiveness is improved, but bioavailability and stability remain poor
Solution Approach 1:
The patent creates a composite structure combining PEG (polyethylene glycol) with rapamycin derivatives. The PEG component provides improved bioavailability and stability, while the rapamycin component maintains immunosuppressive and antitumor activity. This composite material approach allows both properties to coexist and work synergistically.
Solution Approach 2:
The PEG molecule acts as an intermediary carrier between the rapamycin drug molecules and the biological system. It mediates the delivery of rapamycin, improving its bioavailability and stability while allowing the drug to exert its therapeutic effects. The PEG-rapamycin conjugate serves as the intermediate form that bridges the gap between poor drug properties and therapeutic requirements.
3Quantity of substance
If multiple rapamycin molecules are linked to each PEG terminal group, then drug loading rate increases, but reaction completeness becomes challenging
Solution Approach 1:
The patent employs preliminary activation of the PEG terminal groups before the actual drug conjugation process. By pre-activating the terminal groups with appropriate chemical groups, the reaction conditions are optimized in advance to ensure complete and efficient bonding with rapamycin molecules, thereby achieving high drug loading rates with complete reactions.
Solution Approach 2:
The patent optimizes reaction parameters such as pH, temperature, and reagent ratios to enhance reaction completeness. By carefully controlling these parameters, the multi-step conjugation process achieves high efficiency and completeness, allowing multiple rapamycin molecules to be successfully attached to each PEG terminal group without significant side reactions or incomplete bonding.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly increases the drug loading rate and bioavailability of rapamycin, providing improved therapeutic effects with enhanced antitumor activity and reduced side effects, as demonstrated by compounds LPR-2 and LPR-3, which show stronger antitumor activity compared to traditional PEG-rapamycin conjugates.
Implementation Method 1
polyethylene glycol-cactus oligopeptide bonding rapamycin derivatives... through a more complete amidation reaction process
Data Source
AI summary
The present invention provides compounds represented by formula (I) and pharmaceutical acceptable salts thereof, preparation method therefor and pharmaceutical composition containing the compounds represented by formula (I) and pharmaceutical acceptable salts thereof. In the compounds of the present invention, each terminal group of polyethylene glycol molecule can bond with a plurality of rapamycin molecules by cactus oligopeptide, with the loading rate of the pharmaceutical being increased. The compounds can be used to induce immunosuppression and treat graft rejection, autoimmune disease, solid tumors, fungal infection, and cardiovascular and cerebrovascular disease.